Recent progress in protein-protein interaction study for EGFR-targeted therapeutics

Feiner R, Müller K (2016)
Expert Review of Proteomics 13(9): 817-832.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Abstract / Bemerkung
Introduction: Epidermal growth factor receptor (EGFR) expression is upregulated in many tumors and its aberrant signaling drives progression of many cancer types. Consequently, EGFR has become a clinically validated target as extracellular tumor marker for antibodies as well as for tyrosine kinase inhibitors. Within the last years, new mechanistic insights were uncovered and, based on clinical experience as well as progress in protein engineering, novel bio-therapeutic approaches were developed and tested.Areas covered: The potential therapeutic targeting arsenal in the fight against cancer now encompasses bispecific or biparatopic antibodies, DARPins, Adnectins, Affibodies, peptides and combinations of these binding molecules with viral- and nano-particles. We review past and recent binding proteins from the literature and include a brief description of the various targeting approaches. Special attention is given to the binding modes with the EGFR.Expert commentary: Clinical data from the three approved anti EGFR antibodies indicate that there is room for improved therapeutic efficacy. Having choices in size, affinity, avidity and the mode of EGFR binding as well as the possibility to combine various effector functions opens the possibility to rationally design more effective therapeutics.
Erscheinungsjahr
Zeitschriftentitel
Expert Review of Proteomics
Band
13
Zeitschriftennummer
9
Seite
817-832
ISSN
eISSN
PUB-ID

Zitieren

Feiner R, Müller K. Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics. 2016;13(9):817-832.
Feiner, R., & Müller, K. (2016). Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics, 13(9), 817-832. doi:10.1080/14789450.2016.1212665
Feiner, R., and Müller, K. (2016). Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics 13, 817-832.
Feiner, R., & Müller, K., 2016. Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics, 13(9), p 817-832.
R. Feiner and K. Müller, “Recent progress in protein-protein interaction study for EGFR-targeted therapeutics”, Expert Review of Proteomics, vol. 13, 2016, pp. 817-832.
Feiner, R., Müller, K.: Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics. 13, 817-832 (2016).
Feiner, Rebecca, and Müller, Kristian. “Recent progress in protein-protein interaction study for EGFR-targeted therapeutics”. Expert Review of Proteomics 13.9 (2016): 817-832.

161 References

Daten bereitgestellt von Europe PubMed Central.

Cell signaling by receptor tyrosine kinases.
Lemmon MA, Schlessinger J., Cell 141(7), 2010
PMID: 20602996
The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R Jr., Pharmacol. Res. 79(), 2013
PMID: 24269963
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.
Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J., Nature 309(5967), 1984
PMID: 6328312
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S., Cell 110(6), 2002
PMID: 12297050
Architecture and membrane interactions of the EGF receptor.
Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, Shaw DE., Cell 152(3), 2013
PMID: 23374350
ERBB receptors and cancer: the complexity of targeted inhibitors.
Hynes NE, Lane HA., Nat. Rev. Cancer 5(5), 2005
PMID: 15864276
Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor.
Bessman NJ, Bagchi A, Ferguson KM, Lemmon MA., Cell Rep 9(4), 2014
PMID: 25453753
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S., Mol. Cell 12(3), 2003
PMID: 14527402
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA., Mol. Cell 11(2), 2003
PMID: 12620237
Spatial control of EGF receptor activation by reversible dimerization on living cells.
Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I., Nature 464(7289), 2010
PMID: 20208517
Architecture and membrane interactions of the EGF receptor.
Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, Shaw DE., Cell 152(3), 2013
PMID: 23374350
A single ligand is sufficient to activate EGFR dimers.
Liu P, Cleveland TE 4th, Bouyain S, Byrne PO, Longo PA, Leahy DJ., Proc. Natl. Acad. Sci. U.S.A. 109(27), 2012
PMID: 22699492
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.
Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J., Mol. Cell 42(1), 2011
PMID: 21474065
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J., Proc. Natl. Acad. Sci. U.S.A. 106(51), 2009
PMID: 20007378
Functional selectivity of EGF family peptide growth factors: implications for cancer.
Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd., Pharmacol. Ther. 122(1), 2008
PMID: 19135477
Conformational coupling across the plasma membrane in activation of the EGF receptor.
Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, Shan Y, Shaw DE, Wemmer DE, Groves JT, Kuriyan J., Cell 152(3), 2013
PMID: 23374349
Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.
Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J., Cell 137(7), 2009
PMID: 19563760
Untangling the ErbB signalling network.
Yarden Y, Sliwkowski MX., Nat. Rev. Mol. Cell Biol. 2(2), 2001
PMID: 11252954
PI3K signalling: the path to discovery and understanding.
Vanhaesebroeck B, Stephens L, Hawkins P., Nat. Rev. Mol. Cell Biol. 13(3), 2012
PMID: 22358332
Mammalian phospholipase C.
Kadamur G, Ross EM., Annu. Rev. Physiol. 75(), 2012
PMID: 23140367
EGF receptor ligands.
Harris RC, Chung E, Coffey RJ., Exp. Cell Res. 284(1), 2003
PMID: 12648462
ADAMs: key components in EGFR signalling and development.
Blobel CP., Nat. Rev. Mol. Cell Biol. 6(1), 2005
PMID: 15688065
EGFR signal transactivation in cancer cells.
Fischer OM, Hart S, Gschwind A, Ullrich A., Biochem. Soc. Trans. 31(Pt 6), 2003
PMID: 14641026
ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
Friedlander E, Barok M, Szollosi J, Vereb G., Immunol. Lett. 116(2), 2007
PMID: 18201769
EGFR and cancer prognosis.
Nicholson RI, Gee JM, Harper ME., Eur. J. Cancer 37 Suppl 4(), 2001
PMID: 11597399
Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study.
Baan JA, Varga ZV, Leszek P, Kusmierczyk M, Baranyai T, Dux L, Ferdinandy P, Braun T, Mendler L., J Transl Med 13(), 2015
PMID: 25591711
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J., Cancer Res. 44(3), 1984
PMID: 6318979
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM., Cancer Cell 7(4), 2005
PMID: 15837620

Rocha-Lima, Cancer Control 2(), 1998
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM., Cancer Cell 13(4), 2008
PMID: 18394559

Yang, Cancer Res 15(59), 1999
Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431.
Haigler H, Ash JF, Singer SJ, Cohen S., Proc. Natl. Acad. Sci. U.S.A. 75(7), 1978
PMID: 356052
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG., Crit. Rev. Oncol. Hematol. 38(1), 2001
PMID: 11255078
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S, Kussie P, Ferguson KM., Structure 16(2), 2008
PMID: 18275813
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM., Cancer Res. 65(2), 2005
PMID: 15695407
Tetravalent miniantibodies with high avidity assembling in Escherichia coli.
Pack P, Muller K, Zahn R, Pluckthun A., J. Mol. Biol. 246(1), 1995
PMID: 7853401
Engineered antibody fragments and the rise of single domains.
Holliger P, Hudson PJ., Nat. Biotechnol. 23(9), 2005
PMID: 16151406
Antibody fragments: hope and hype.
Nelson AL., MAbs 2(1), 2010
PMID: 20093855
Development trends for generation of single-chain antibody fragments.
Farajnia S, Ahmadzadeh V, Tanomand A, Veisi K, Khosroshahi SA, Rahbarnia L., Immunopharmacol Immunotoxicol 36(5), 2014
PMID: 25081575
Analysis of renal handling of radiopharmaceuticals.
Trejtnar F, Laznicek M., Q J Nucl Med 46(3), 2002
PMID: 12134135
A dimeric bispecific miniantibody combines two specificities with avidity.
Muller KM, Arndt KM, Pluckthun A., FEBS Lett. 432(1-2), 1998
PMID: 9710248
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, Schaller E, Herrmann I, Wolf A, Urbig T, Baeuerle PA, Kufer P., Proc. Natl. Acad. Sci. U.S.A. 107(28), 2010
PMID: 20616015
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G., Science 323(5921), 2009
PMID: 19299620
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C., Cancer Cell 20(4), 2011
PMID: 22014573
Immunoglobulin isotype knowledge and application to Fc engineering.
Brezski RJ, Georgiou G., Curr. Opin. Immunol. 40(), 2016
PMID: 27003675
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A., Clin. Cancer Res. 22(10), 2016
PMID: 27179112

AUTHOR UNKNOWN, 0
Antibody-drug conjugates: an emerging concept in cancer therapy.
Chari RV, Miller ML, Widdison WC., Angew. Chem. Int. Ed. Engl. 53(15), 2014
PMID: 24677743
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.
Koefoed K, Steinaa L, Soderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW., MAbs 3(6), 2011
PMID: 22123060
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB., Mol. Cancer Ther. 14(7), 2015
PMID: 25911688

Arena, Sci Transl Med 8(324), 2016
A recurring theme in protein engineering: the design, stability and folding of repeat proteins.
Main ER, Lowe AR, Mochrie SG, Jackson SE, Regan L., Curr. Opin. Struct. Biol. 15(4), 2005
PMID: 16043339
A novel strategy to design binding molecules harnessing the modular nature of repeat proteins.
Forrer P, Stumpp MT, Binz HK, Pluckthun A., FEBS Lett. 539(1-3), 2003
PMID: 12650916
Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments.
Interlandi G, Wetzel SK, Settanni G, Pluckthun A, Caflisch A., J. Mol. Biol. 375(3), 2007
PMID: 18048057
Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.
Steiner D, Forrer P, Pluckthun A., J. Mol. Biol. 382(5), 2008
PMID: 18706916
DARPins and other repeat protein scaffolds: advances in engineering and applications.
Boersma YL, Pluckthun A., Curr. Opin. Biotechnol. 22(6), 2011
PMID: 21715155
Structural principles of leucine-rich repeat (LRR) proteins.
Enkhbayar P, Kamiya M, Osaki M, Matsumoto T, Matsushima N., Proteins 54(3), 2004
PMID: 14747988
Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering.
Lee SC, Park K, Han J, Lee JJ, Kim HJ, Hong S, Heu W, Kim YJ, Ha JS, Lee SG, Cheong HK, Jeon YH, Kim D, Kim HS., Proc. Natl. Acad. Sci. U.S.A. 109(9), 2012
PMID: 22328160
Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy.
Lee JJ, Choi HJ, Yun M, Kang Y, Jung JE, Ryu Y, Kim TY, Cha YJ, Cho HS, Min JJ, Chung CW, Kim HS., Angew. Chem. Int. Ed. Engl. 54(41), 2015
PMID: 26315561
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy.
Sihver W, Pietzsch J, Krause M, Baumann M, Steinbach J, Pietzsch HJ., Pharmaceuticals (Basel) 7(3), 2014
PMID: 24603603
Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor.
Cuartero-Plaza A, Martinez-Miralles E, Rosell R, Vadell-Nadal C, Farre M, Real FX., Clin. Cancer Res. 2(1), 1996
PMID: 9816084
Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J, Stahl S., Protein Eng. Des. Sel. 20(4), 2007
PMID: 17452435
Non-immunoglobulin based protein scaffolds.
Lofblom J, Frejd FY, Stahl S., Curr. Opin. Biotechnol. 22(6), 2011
PMID: 21726995

AUTHOR UNKNOWN, 0
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V, Rosik D, Wallberg H, Sjoberg A, Sandstrom M, Hansson M, Wennborg A, Orlova A., Eur. J. Nucl. Med. Mol. Imaging 37(3), 2009
PMID: 19838701
Crystal structure of the tenth type III cell adhesion module of human fibronectin.
Dickinson CD, Veerapandian B, Dai XP, Hamlin RC, Xuong NH, Ruoslahti E, Ely KR., J. Mol. Biol. 236(4), 1994
PMID: 8120888
The fibronectin type III domain as a scaffold for novel binding proteins.
Koide A, Bailey CW, Huang X, Koide S., J. Mol. Biol. 284(4), 1998
PMID: 9837732
Stability and CDR composition biases enrich binder functionality landscapes.
Hackel BJ, Ackerman ME, Howland SW, Wittrup KD., J. Mol. Biol. 401(1), 2010
PMID: 20540948
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL, Engle LJ, Chao G, Zhu RR, Cao C, Lin Z, Yamniuk AP, Hosbach J, Brown J, Fitzpatrick E, Gokemeijer J, Morin P, Morse BA, Carvajal IM, Fabrizio D, Wright MC, Das Gupta R, Gosselin M, Cataldo D, Ryseck RP, Doyle ML, Wong TW, Camphausen RT, Cload ST, Marsh HN, Gottardis MM, Furfine ES., MAbs 3(1), 2011
PMID: 21099371
Structures of adnectin/protein complexes reveal an expanded binding footprint.
Ramamurthy V, Krystek SR Jr, Bush A, Wei A, Emanuel SL, Das Gupta R, Janjua A, Cheng L, Murdock M, Abramczyk B, Cohen D, Lin Z, Morin P, Davis JH, Dabritz M, McLaughlin DC, Russo KA, Chao G, Wright MC, Jenny VA, Engle LJ, Furfine E, Sheriff S., Structure 20(2), 2012
PMID: 22325775
Fast photochemical oxidation of proteins (FPOP) maps the epitope of EGFR binding to adnectin.
Yan Y, Chen G, Wei H, Huang RY, Mo J, Rempel DL, Tymiak AA, Gross ML., J. Am. Soc. Mass Spectrom. 25(12), 2014
PMID: 25267085
Nanobodies as novel agents for cancer therapy.
Revets H, De Baetselier P, Muyldermans S., Expert Opin Biol Ther 5(1), 2005
PMID: 15709914
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies.
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S., FEBS Lett. 414(3), 1997
PMID: 9323027
Nanobody-based cancer therapy of solid tumors.
Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM., Nanomedicine (Lond) 10(1), 2015
PMID: 25597775
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PM., Cancer Immunol. Immunother. 56(3), 2007
PMID: 16738850
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM., Structure 21(7), 2013
PMID: 23791944
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM., Int. J. Cancer 129(8), 2011
PMID: 21520037
Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif.
Heukers R, Vermeulen JF, Fereidouni F, Bader AN, Voortman J, Roovers RC, Gerritsen HC, van Bergen En Henegouwen PM., J. Cell. Sci. 126(Pt 21), 2013
PMID: 23943881
Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, van Bergen en Henegouwen PM, Storm G, Hennink WE, Schiffelers RM, Kok RJ., J Control Release 159(2), 2011
PMID: 22227023
Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, Storm G, Roovers RC., J Control Release 145(2), 2010
PMID: 20362020
Peptide mimics of epidermal growth factor (EGF) with antagonistic activity.
Nakamura T, Takasugi H, Aizawa T, Yoshida M, Mizuguchi M, Mori Y, Shinoda H, Hayakawa Y, Kawano K., J. Biotechnol. 116(3), 2005
PMID: 15707681
Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo.
Song S, Liu D, Peng J, Deng H, Guo Y, Xu LX, Miller AD, Xu Y., FASEB J. 23(5), 2009
PMID: 19124558
Evaluation of dimerization-inhibitory activities of cyclic peptides containing a β-hairpin loop sequence of the EGF receptor.
Mizuguchi T, Ohara N, Iida M, Ninomiya R, Wada S, Kiso Y, Saito K, Akaji K., Bioorg. Med. Chem. 20(19), 2012
PMID: 22959765
Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics.
Hanold LE, Oruganty K, Ton NT, Beedle AM, Kannan N, Kennedy EJ., PLoS ONE 10(3), 2015
PMID: 25790232
Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.
Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK., J. Biol. Chem. 288(37), 2013
PMID: 23897823
Trojan horse at cellular level for tumor gene therapies.
Collet G, Grillon C, Nadim M, Kieda C., Gene 525(2), 2013
PMID: 23542073

AUTHOR UNKNOWN, 0
Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Altintas I, Heukers R, van der Meel R, Lacombe M, Amidi M, van Bergen En Henegouwen PM, Hennink WE, Schiffelers RM, Kok RJ., J Control Release 165(2), 2012
PMID: 23159529

Mamot, Control (63), 2003
Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy.
Hagen S, Baumann T, Wagner HJ, Morath V, Kaufmann B, Fischer A, Bergmann S, Schindler P, Arndt KM, Muller KM., Sci Rep 4(), 2014
PMID: 24457557
Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.
Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J., Cancer Gene Ther. 16(3), 2008
PMID: 18927600
Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma.
Verheije MH, Lamfers ML, Wurdinger T, Grinwis GC, Gerritsen WR, van Beusechem VW, Rottier PJ., J. Virol. 83(15), 2009
PMID: 19439466
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J., Clin. Cancer Res. 1(11), 1995
PMID: 9815926
Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R., Immunotechnology 3(1), 1997
PMID: 9154469
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, van de Winkel JG, Parren PW., J. Immunol. 173(7), 2004
PMID: 15383606
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide.
Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M., Arch. Biochem. Biophys. 252(2), 1987
PMID: 2434025
Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.
Wersall P, Ohlsson I, Biberfeld P, Collins VP, von Krusenstjerna S, Larsson S, Mellstedt H, Boethius J., Cancer Immunol. Immunother. 44(3), 1997
PMID: 9191875
Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM., Protein Eng. 4(7), 1991
PMID: 1798701

AUTHOR UNKNOWN, 0
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umana P., Clin. Cancer Res. 19(5), 2012
PMID: 23209031
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM., Br. J. Cancer 92(6), 2005
PMID: 15770208

Phillips, Mol Cancer Ther 128(2), 2016
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, Bigner DD., Nucl. Med. Biol. 39(1), 2011
PMID: 21958852
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD., Clin. Cancer Res. 19(17), 2013
PMID: 23857604
The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells.
Gooi HC, Hounsell EF, Lax I, Kris RM, Libermann TA, Schlessinger J, Sato JD, Kawamoto T, Mendelsohn J, Feizi T., Biosci. Rep. 5(1), 1985
PMID: 2580573
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I., Proc. Natl. Acad. Sci. U.S.A. 93(25), 1996
PMID: 8962138
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.
Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T., Mol Imaging Biol 10(3), 2008
PMID: 18297364
Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
Nevoltris D, Lombard B, Dupuis E, Mathis G, Chames P, Baty D., ACS Nano 9(2), 2015
PMID: 25603171
Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
Friedman M, Orlova A, Johansson E, Eriksson TL, Hoiden-Guthenberg I, Tolmachev V, Nilsson FY, Stahl S., J. Mol. Biol. 376(5), 2008
PMID: 18207161
Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution.
Hackel BJ, Sathirachinda A, Gambhir SS., Protein Eng. Des. Sel. 25(10), 2012
PMID: 22691700
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, Zhu Z., J. Biol. Chem. 279(4), 2003
PMID: 14576153
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z., J. Biol. Chem. 280(20), 2005
PMID: 15757893
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH., Proc. Natl. Acad. Sci. U.S.A. 110(1), 2012
PMID: 23248284
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, Scheuer W, Venturi M, Klein C, Niederfellner G, Sustmann C., Oncogene 32(50), 2013
PMID: 23812422

Lee, Oncogene (), 2016
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W., Cancer Res. 75(1), 2014
PMID: 25371409
Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG., Clin. Cancer Res. 12(1), 2006
PMID: 16397041
Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.
Shubbar E, Kovacs A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdottir K, Einbeigi Z, Karlsson P, Helou K., BMC Cancer 13(), 2013
PMID: 23282137
Dianthin-EGF is an effective tumor targeted toxin in combination with saponins in a xenograft model for colon carcinoma.
von Mallinckrodt B, Thakur M, Weng A, Gilabert-Oriol R, Durkop H, Brenner W, Lukas M, Beindorff N, Melzig MF, Fuchs H., Future Oncol 10(14), 2014
PMID: 25471031

Li, Drug Deliv (), 2016
Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting.
Li X, Qiu L, Zhu P, Tao X, Imanaka T, Zhao J, Huang Y, Tu Y, Cao X., Small 8(16), 2012
PMID: 22619186
Design of a selenylsulfide-bridged EGFR dimerization arm mimic.
Hanold LE, Watkins CP, Ton NT, Liaw P, Beedle AM, Kennedy EJ., Bioorg. Med. Chem. 23(12), 2015
PMID: 25840798
Inhibitory effect of a dimerization-arm-mimetic peptide on EGF receptor activation.
Mizuguchi T, Uchimura H, Kakizawa T, Kimura T, Yokoyama S, Kiso Y, Saito K., Bioorg. Med. Chem. Lett. 19(12), 2009
PMID: 19419869
Design of a novel small peptide targeted against a tumor-specific receptor.
Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF Jr., Biochem. Biophys. Res. Commun. 275(2), 2000
PMID: 10964715
From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.
Cardo-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R., Proc. Natl. Acad. Sci. U.S.A. 107(11), 2010
PMID: 20190183

AUTHOR UNKNOWN, 0
Cloning of a novel EGFR-related peptide: a putative negative regulator of EGFR.
Yu Y, Rishi AK, Turner JR, Liu D, Black ED, Moshier JA, Majumdar AP., Am. J. Physiol., Cell Physiol. 280(5), 2001
PMID: 11287320

Hagen, Sci Rep 4(3759), 2014
Rescue and propagation of fully retargeted oncolytic measles viruses.
Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ., Nat. Biotechnol. 23(2), 2005
PMID: 15685166
The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery.
Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE., Gene Ther. 4(10), 1997
PMID: 9415305
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule.
Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT., Cancer Res. 61(17), 2001
PMID: 11522629
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.
Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grutter MG, Belousova N, Mikheeva G, Krasnykh V, Pluckthun A., Proc. Natl. Acad. Sci. U.S.A. 110(10), 2013
PMID: 23431166
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL., Hum. Gene Ther. 26(5), 2015
PMID: 25919378
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.
Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO., Cancer Gene Ther. 17(9), 2010
PMID: 20508670
A ligand-pseudoreceptor system based on de novo designed peptides for the generation of adenoviral vectors with altered tropism.
Zeng Y, Pinard M, Jaime J, Bourget L, Uyen Le P, O'Connor-McCourt MD, Gilbert R, Massie B., J Gene Med 10(4), 2008
PMID: 18189335
EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene.
Grunwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Goke B, Holm PS, Ogris M, Spitzweg C., Mol Ther Nucleic Acids 2(), 2013
PMID: 24193032
Biodistribution and antitumor effect of Cetuximab-targeted lentivirus.
Huhtala T, Kaikkonen MU, Lesch HP, Viitala S, Yla-Herttuala S, Narvanen A., Nucl. Med. Biol. 41(1), 2013
PMID: 24267054
(Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery.
Kaikkonen MU, Lesch HP, Pikkarainen J, Raty JK, Vuorio T, Huhtala T, Taavitsainen M, Laitinen T, Tuunanen P, Grohn O, Narvanen A, Airenne KJ, Yla-Herttuala S., Gene Ther. 16(7), 2009
PMID: 19440224

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 27424502
PubMed | Europe PMC

Suchen in

Google Scholar